These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20116341)

  • 1. Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with (131)Cs brachytherapy for prostate cancer.
    Gokhale AS; Beriwal S; Smith RP; Li X; Benoit R
    Brachytherapy; 2010; 9(4):328-34. PubMed ID: 20116341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute bowel morbidity after prostate brachytherapy with cesium-131.
    Jacobs BL; Gibbons EP; Smith RP; Beriwal S; Benoit RM
    Brachytherapy; 2011; 10(1):51-6. PubMed ID: 20797922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for optimal dose-volume constraints to reduce rectal toxicity after hypofractionated radiotherapy for prostate cancer.
    Faria S; Joshua B; Patrocinio H; Dal Pra A; Cury F; Velly AM; Souhami L
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):810-7. PubMed ID: 20980135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
    Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin J; Lizarde J; Macedo J; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):824-30. PubMed ID: 20510195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors.
    Shah JN; Ennis RD
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):817-24. PubMed ID: 16297567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Albertsen PC
    J Urol; 2005 Nov; 174(5):1969-70. PubMed ID: 16217368
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
    Vavassori V; Fiorino C; Rancati T; Magli A; Fellin G; Baccolini M; Bianchi C; Cagna E; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Valdagni R
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1401-10. PubMed ID: 17241754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131.
    Jacobs BL; Smith RP; Beriwal S; Benoit RM
    Urology; 2010 Nov; 76(5):1143-7. PubMed ID: 20627283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
    Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
    Fonteyne V; De Neve W; Villeirs G; De Wagter C; De Meerleer G
    Radiother Oncol; 2007 Aug; 84(2):156-63. PubMed ID: 17692976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
    Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
    Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.